You can view the research column published every month by SMC Laboratories.
2025.02.02
Preclinical studies for COPD research: PPE model
We would like to share with you about our Porcine pancreatic elastase (PPE)-induced pulmonary emphysema model…
READ MORE
2025.02.02
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunct…
READ MORE
2025.02.02
New drugs for chronic kidney disease are desired
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, ho…
READ MORE
2025.02.02
Clinically correlated gut dysfunction in liver disease model
We would like to share with you our presentation from the 5th Korea Digestive Disease Week (KDDW 2021) (Novemb…
READ MORE
2025.02.02
Combination study with our proprietary NASH-HCC model
We would like to introduce the combination study using NASH model mice. Combination study in NASH These…
READ MORE
2025.02.02
SSc-ILD mouse model for simultaneous development of skin and lung fibrosis
We would like to introduce our SSc-ILD model – an improvement on our existing systemic scleroderma model – whi…
READ MORE
2025.02.02
Acute Lung Injury mouse model shows similar symptoms to COVID-19 patients
We would like to introduce the Liposaccharide-induced Acute Lung Injury model (LPS model) – an ARDS model that…
READ MORE
2025.02.02
Liver Orthotopic Xenograft mouse model
We would like to introduce the Liver Orthotopic Xenograft mouse model – a cancer model that also allows the ev…
READ MORE
2025.02.02
Performance of FXR agonist pharmacology studies using our NASH model
We would like to share with you about our experience evaluating farnesoid X receptor (FXR) agonists in the wor…
READ MORE
2025.02.02
Introduction of our original chronic liver disease model mouse
We would like to introduce today the world’s first mouse model that induces liver cancer from nonalcohol…
READ MORE
